Treatment Information

Back

Ovarian Cancer treatment details. Chemotherapy, Biologic therapy.

Washington University School of Medicine, St. Louis, MO, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:St. Louis, MO
Treatments:Chemotherapy, Biologic therapyHospital:Washington University School of Medicine
Drugs:Journal:Link
Date:Dec 2013

Description:

Patients:
This phase 2 study involved 34 patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancers who had received prior chemotherapy. The average patient age was 61.5 years.

Treatment:
Patients were treated with the biologic therapy agent bevacizumab and the chemotherapy agent pemetrexed.

Toxicities:
There was one treatment-related death attributed to constitutional effects (ie. fatigue, insomnia, weight changes). Grade 4 neutropenia, leukopenia, thrombocytopenia, and pain were also reported.

Results:
The median overall survival was 25.7 months.

Support:
This study was partially supported by Eli Lilly and Genentech.

Correspondence: Dr. Andrea R. Hagemann; email: [email protected]



Back